Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for aTyr Pharma, Inc. (ATYR : NSDQ)

• Company Description    aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. Number of Employees: 58

• Price / Volume Information    Yesterday's Closing Price: $0.49 Daily Weekly Monthly 20 Day Moving Average: 3,624,036 shares Shares Outstanding: 98.05 (millions) Market Capitalization: $48.04 (millions) Beta: 0.66 52 Week High: $7.29 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -38.11% -41.13% 12 Week -50.50% -54.24% Year To Date -37.43% -37.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10240 Sorrento Valley Road Suite 300 - SAN DIEGO,CA 92121 USA ph: 858-731-8389 fax: 858-731-8394 investorrelations@atyrpharma.com http://www.atyrpharma.com

• General Corporate Information    Officers Sanjay S. Shukla - President; Chief Executive Officer and Director Timothy P. Coughlin - Chairman of the Board Jill M. Broadfoot - Chief Financial Officer Eric Benevich - Director Jane A. Gross - Director Peer Information aTyr Pharma, Inc. (CORR.) aTyr Pharma, Inc. (RSPI) aTyr Pharma, Inc. (CGXP) aTyr Pharma, Inc. (BGEN) aTyr Pharma, Inc. (GTBP) aTyr Pharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 002120202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 98.05 Most Recent Split Date: 7.00 (0.07:1) Beta: 0.66 Market Capitalization: $48.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.83 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.29% vs. Previous Quarter: 21.43% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -100.14 12/31/25 - -99.87 09/30/25 - -100.36 ROA 03/31/26 - -73.55 12/31/25 - -74.41 09/30/25 - -74.70 Current Ratio 03/31/26 - 5.78 12/31/25 - 5.30 09/30/25 - 5.93 Quick Ratio 03/31/26 - - 12/31/25 - 5.30 09/30/25 - 5.93 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -36,860.00 12/31/25 - -39,012.11 09/30/25 - -39,540.53 Book Value 03/31/26 - 0.59 12/31/25 - 0.69 09/30/25 - 0.82 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.26 12/31/25 - 0.38 09/30/25 - 0.49

Powered by Zacks Investment Research ©